Using adjunctive hydrocortisone therapy yields a significant monetized benefit based on inputs from the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock and Activated Protein C and Corticosteroids for Human Septic Shock trials.

Per Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock, adjunctive hydrocortisone therapy showed a 90-day monetized benefit of $8,111 per patient, driven by improvements in ICU-free days, vasopressor-free days, ventilation-free days, and blood transfusion proportion.

The total estimated annual impact of adjunctive hydrocortisone therapy, in 2019 dollars, was $750 million.

Per Activated Protein C and Corticosteroids for Human Septic Shock, adjunctive hydrocortisone therapy showed a 90-day monetized benefit of $25,539 per patient, driven by improvements in ICU free-days, vasopressor-free days, and ventilation-free days.

The total estimated annual impact of adjunctive hydrocortisone therapy, in 2019 dollars, was $2.3 billion.

Read More